MNTA Momenta Pharmaceuticals Inc.

52.4
+0.01  (+0%)
Previous Close 52.39
Open 52.4
52 Week Low 12.21
52 Week High 52.45
Market Cap $6,233,777,738
Shares 118,965,224
Float 71,470,025
Enterprise Value $5,834,566,737
Volume 2,064,363
Av. Daily Volume 3,797,677
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
M254
Immune Thrombocytopenic Purpura (ITP)
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Nipocalimab (M281)
Hemolytic disease of the fetus and newborn (HDFN)
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2
Phase 2
Phase 2 trial met primary endpoint - June 15, 2020. Phase 3 trial to be initiated 1Q 2021.
M254
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Phase 2
Phase 2
Phase 2 trial to be initiated in 2021.
Nipocalimab (M281)
Warm Autoimmune Hemolytic Anemia (wAIHA)
Phase 2/3
Phase 2/3
Phase 2 trial to recommence enrollment 4Q 2020.
M230 (CSL730)
Healthy volunteers
Phase 1
Phase 1
Phase 1 initiation 2020.
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1/2
Phase 1/2
Phase 2 development discontinued due to poor efficacy shown
Generic Copaxone
Multiple sclerosis
Approved
Approved
Filed 2007. Approved April 16 2015.

Latest News

  1. NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals Inc (NASD:MNTA) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, October 1. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Momenta Pharmaceuticals in a deal expected to be completed soon pending final conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    October 1, 2020

    S&P SmallCap 600

    Addition

    Chesapeake Utilities

    CPK

    Utilities

    October 1, 2020

    S&P SmallCap 600

    Deletion

    Momenta Pharmaceuticals

    MNTA

    Health Care

    For more information about S&P Dow…

    NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals Inc (NASD:MNTA) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, October 1. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Momenta Pharmaceuticals in a deal expected to be completed soon pending final conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    October 1, 2020

    S&P SmallCap 600

    Addition

    Chesapeake Utilities

    CPK

    Utilities

    October 1, 2020

    S&P SmallCap 600

    Deletion

    Momenta Pharmaceuticals

    MNTA

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    Media Inquiries

     

    Cision View original content:http://www.prnewswire.com/news-releases/chesapeake-utilities-to-join-sp-smallcap-600-301138429.html

    SOURCE S&P Dow Jones Indices

    View Full Article Hide Full Article
  2. NEW YORK, Sept. 17, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

    Varian Medical Systems, Inc. (NYSE:VAR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Siemens Healthineers AG for $177.50 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/varian-medical-systems-inc-var-stock-merger-siemens.

    Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/momenta-pharmaceuticals-inc-stock-merger-jnj.

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sociétés des Produits Nestlé, S.A. for $34.50 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/aimmune-therapeutics-inc-aimt-stock-merger-nestle/.

    GCI Liberty, Inc. (NASDAQ:GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Liberty Broadband Corporation. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/gci-liberty-inc-gliba-stock-merger-liberty-broadband-technologies/.

    Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

    Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email  or .

    Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

    Attorney Advertising. Prior results do not guarantee a similar outcome.

    Contact Information:

    Halper Sadeh LLP

    Daniel Sadeh, Esq.

    Zachary Halper, Esq.

    (212) 763-0060



      

    https://www.halpersadeh.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alert-halper-sadeh-llp-is-investigating-the-following-mergers-shareholders-are-encouraged-to-contact-the-firm-301133561.html

    SOURCE Halper Sadeh LLP

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA, "Momenta" or the "Company"))), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with the all-cash tender offer by Vigor Sub, Inc. ("Vigor"), a wholly owned subsidiary of Johnson & Johnson ("Johnson & Johnson" or "J&J"), for all the outstanding shares of Momenta common stock for $52.50 per share (the "Offer Price").  The tender offer, which commenced on September 2, 2020, is being made pursuant to the previously announced…

    CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA, "Momenta" or the "Company"))), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with the all-cash tender offer by Vigor Sub, Inc. ("Vigor"), a wholly owned subsidiary of Johnson & Johnson ("Johnson & Johnson" or "J&J"), for all the outstanding shares of Momenta common stock for $52.50 per share (the "Offer Price").  The tender offer, which commenced on September 2, 2020, is being made pursuant to the previously announced merger agreement among Johnson & Johnson, Vigor and Momenta, dated August 19, 2020 (the "Merger Agreement").

    With the expiration of the waiting period, the transaction is expected to close in early October 2020, subject to the satisfaction of all remaining closing conditions set forth in the Merger Agreement.  Unless the tender offer is extended, the tender offer will expire at 12:00 midnight, New York City time, at the end of the day on September 30, 2020.

    Following the completion of the tender offer, Johnson & Johnson expects to consummate a merger of Momenta with Vigor as soon as practicable, in which shares of Momenta that have not been tendered in the tender offer will be acquired by Johnson & Johnson and converted into the right to receive the Offer Price.  The Merger Agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson and includes customary termination provisions for both Momenta and Johnson & Johnson.  The Momenta Board of Directors has unanimously recommended that Momenta stockholders tender their shares pursuant to the tender offer.

    About Momenta



    Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio. The Company is headquartered in Cambridge, MA.

    To learn more about Momenta, please visit www.momentapharma.com, which does not form a part of this press release.

    Momenta's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

    Forward-Looking Statements 

    Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the timing of completion of the tender offer and transaction; and product development goals. Forward-looking statements may be identified by words and phrases such as "advance," "anticipate," "being developed," "believe," "continue," "expect," "guidance," "look forward to," "may," "plan," "possible," "potential," "progress," "propose," "remains," "target," "will," "working toward" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including: (i) uncertainties as to the timing of the completion of the tender offer and the subsequent merger; (ii) the risk that the tender offer or the subsequent merger may not be completed in a timely manner or at all; (iii) uncertainties as to the percentage of Momenta's stockholders tendering their shares in the tender offer; (iv) the possibility that competing offers or acquisition proposals for Momenta will be made; (v) the possibility that any or all of the various conditions to the consummation of the tender offer or the subsequent merger may not be satisfied or waived; (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement among Johnson & Johnson, Vigor and Momenta, including in circumstances which would require Momenta to pay a termination fee; (vii) the effect of the announcement or pendency of the transactions contemplated by the merger agreement on Momenta's ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (viii) risks related to diverting management's attention from Momenta's ongoing business operations; (ix) the risk that stockholder litigation in connection with the transactions contemplated by the merger agreement may result in significant costs of defense, indemnification and liability; and (x) those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2020, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

    INVESTOR CONTACT:

    Patty Eisenhaur

    Momenta Pharmaceuticals

    1-617-395-5189

    MEDIA CONTACT:

    Karen Sharma

    MacDougall

    781-235-3060

    Additional Information and Where to Find It 

    This communication is for informational purposes only and is not an offer to buy nor a solicitation of an offer to sell any securities of Momenta. The solicitation and the offer to buy shares of Momenta's common stock has been made pursuant to a tender offer statement on Schedule TO, as amended, including an offer to purchase, a letter of transmittal and other related materials that Johnson & Johnson and Vigor have filed with the Securities and Exchange Commission ("SEC"). In addition, Momenta has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9, as amended, with respect to the tender offer. Investors may obtain a free copy of these materials and other documents filed by Johnson & Johnson, Vigor and Momenta with the SEC at the website maintained by the SEC at www.sec.gov.  Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by Momenta under the "Investors & News" section of Momenta's website at www.momentapharma.com or by directing a request to Momenta at +1-617-395-5189. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT OF MOMENTA AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES IN THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.

    Primary Logo

    View Full Article Hide Full Article
  4. NEW YORK, Aug. 22, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

    MVC Capital, Inc. (NYSE:MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC and $0.39492 in cash for each share of MVC Capital stock. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/mvc-capital-inc-mvc-stock-merger-barings-bdc.

    Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for $100 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/principia-biopharma-inc-prnb-stock-merger-sanofi/.

    Yintech Investment Holdings Limited (NASDAQ:YIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a group of rollover shareholders that includes members of Yintech's management and board of directors. Under the terms of the merger agreement, holders of Yintech ordinary shares will receive $0.365 in cash per share, and holders of Yintech American depository shares ("ADS"), each representing twenty shares, will receive $7.30 in cash per ADS. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/yintech-investment-holdings-limited-yin-stock-merger/.

    Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/momenta-pharmaceuticals-inc-stock-merger-jnj.

    Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

    Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email  or .

    Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

    Attorney Advertising. Prior results do not guarantee a similar outcome.

    Contact Information:

    Halper Sadeh LLP

    Daniel Sadeh, Esq.

    Zachary Halper, Esq.

    (212) 763-0060



      

    https://www.halpersadeh.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-investigation-alert-halper-sadeh-llp-investigates-the-following-mergers-shareholders-are-encouraged-to-contact-the-firm--mvc-prnb-yin-mnta-301116669.html

    SOURCE Halper Sadeh LLP

    View Full Article Hide Full Article
  5. NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:

    • NTN Buzztime, Inc. (NYSE:NTN)

    NTN Buzztime has signed an agreement to merge with Brooklyn ImmunoTherapeutics. Under the proposed transaction, shareholders of NTN will own only 5.92% of the combined company.

    • Principia Biopharma Inc. (NASDAQ: PRNB)

    Principia Biopharma has agreed to be acquired by Sanofi.  Under the proposed transaction, shareholders of Principia will receive $100.00 in cash for every share owned.

    • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals has agreed to be acquired by Johnson & Johnson.  Under the proposed transaction, shareholders of Momenta will receive $52.50 in cash for every share owned.

    • Pfenex Inc. (NYSE:PFNX)

    Pfenex has agreed to be acquired by Ligand Pharmaceuticals.  Under the proposed transaction, shareholders of Pfenex will receive $12.00 in cash and one contingent value right  for every share owned.

    Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. 

    Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at or telephone at (212) 709-8245.  The consultation and case are free with no obligation to you.  Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

    Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.  For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contacts:

    Moore Kuehn, PLLC

    Justin Kuehn, Esq.

    30 Wall Street, 8th Floor

    New York, New York 10005

     

    (212) 709-8245

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-encourages-ntn-prnb-mnta-and-pfnx-investors-to-contact-law-firm-301115916.html

    SOURCE Moore Kuehn, PLLC

    View Full Article Hide Full Article
View All Momenta Pharmaceuticals Inc. News